Detalhe da pesquisa
1.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol
; 184: 168-177, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38325276
2.
Factors that Influence Treatment Delay for Patients with Breast Cancer.
Ann Surg Oncol
; 28(7): 3714-3721, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33247362
3.
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
JAMA Netw Open
; 7(4): e247811, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648056
4.
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Eur J Cancer
; 182: 3-14, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706655
5.
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
J Clin Oncol
; 41(30): 4768-4778, 2023 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37643382
6.
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Clin Cancer Res
; 29(20): 4068-4075, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581616
7.
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network.
Cancers (Basel)
; 14(8)2022 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35454870
8.
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
J Clin Oncol
; 38(32): 3753-3762, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822286